MARKET

TYRA

TYRA

TYRA BIOSCIENCES INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.46
+0.24
+1.96%
After Hours: 12.46 0 0.00% 16:00 01/14 EST
OPEN
11.96
PREV CLOSE
12.22
HIGH
12.52
LOW
11.83
VOLUME
96.03K
TURNOVER
--
52 WEEK HIGH
31.36
52 WEEK LOW
11.06
MARKET CAP
514.17M
P/E (TTM)
-31.1812
1D
5D
1M
3M
1Y
5Y
Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ...
Investment company Boxer Capital, Llc (Current Portfolio) buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, Fulcrum Therapeutics Inc, Turning Point Therapeutics Inc, sells Seagen Inc, Amarin Corp PLC, Therapeutics Acquisition Cor...
GuruFocus.com · 12/21/2021 23:38
Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Simply Wall St. · 12/15/2021 14:29
Beware of These 3 Recent IPOs That are Overvalued
StockNews.com · 11/11/2021 15:56
Tyra Biosciences to Present at the 2021 Jefferies London Healthcare Conference
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that TYRA management will participate in a firesid...
PR Newswire · 11/10/2021 21:05
Tyra Biosciences Reports Third Quarter 2021 Financial Results and Highlights
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today reported financial results for the quarter ended September 3...
PR Newswire · 11/03/2021 20:05
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator f...
Benzinga · 09/22/2021 12:22
LIVE MARKETS-U.S. stocks tumble as S&P 500 suffers 50-day fumble
reuters.com · 09/17/2021 20:30
LIVE MARKETS-Investors try to sort out supply shortages
reuters.com · 09/17/2021 17:43
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TYRA. Analyze the recent business situations of TYRA BIOSCIENCES INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
33.33%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TYRA stock price target is 31.00 with a high estimate of 31.00 and a low estimate of 31.00.
High31.00
Average31.00
Low31.00
Current 12.46
EPS
Actual
Estimate
-0.58-0.43-0.29-0.14
Q2 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 25
Institutional Holdings: 26.08M
% Owned: 63.20%
Shares Outstanding: 41.27M
TypeInstitutionsShares
Increased
0
0
New
25
26.08M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
+0.11%
Key Executives
Chief Financial Officer
Esther Van Den Boom
General Counsel
John Healy
Executive Officer/Primary Contact
Dan Bensen
Executive Officer
Todd Harris
Executive Officer
Robert Hudkins
Executive Officer
Ronald Swanson
Director
Rehan Verjee
No Data
About TYRA
Tyra Biosciences, Inc. is a precision oncology company. The Company is focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The Company uses it proprietary SNAP platform, which enables refinement of structural design through iterative molecular SNAPshots. The Company is focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR), which are altered in approximately 7% of all cancers. Its lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. In addition, it has pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase (RET), and FGFR4-related cancers.

Webull offers kinds of Tyra Biosciences Inc stock information, including NASDAQ:TYRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TYRA stock methods without spending real money on the virtual paper trading platform.